The silent kidneys
By
The International Diabetes Federation projects a global diabetes incidence of 643 million by 2030. Diabetic kidney disease (DKD) occurs in up to 40% of patients with diabetes. Although albumin-creatinine ratio (ACR) is known to be the earliest marker of kidney disease, frequency of ACR testing remains low. Pharmaceutical company Abbott explores how quantitative ACR point-ofcare testing improves DKD diagnosis and is a game-changer for better overall patient management.